Spinal Muscular Atrophy Market Opportunity Assessment and Forecasts 2023-2033 Spinraza's Expected Patent Expiry Will See Cheap Nusinersen Biosimilars Enter the Market and ...

Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and capitalizing on cheap nusinersen ...
BioSpace

Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight

The FDA approved an intrathecal form of Novartis’ spinal muscular atrophy gene therapy Zolgensma on Monday, broadening access ...

Spinal Muscular Atrophy Pipeline Insights Report 2025: Uncovering Breakthrough Drug Candidates Driving Future Market Growth

On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...

Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community

-- Muscular Dystrophy Association Calls FDA Approval of Novartis' Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community Mary Fiance, National Vice ...
Medscape

FDA OKs New Formulation of SMA Gene Therapy Itvisma

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

Cure SMA Welcomes Broad FDA Approval of Itvisma(TM) for Spinal Muscular Atrophy, Reinforces Commitment to Patient Access and Support

SCHAUMBURG, Ill., Nov. 26, 2025 /PRNewswire/ -- Cure SMA, the leading nonprofit organization dedicated to supporting those impacted by spinal muscular atrophy (SMA), welcomes the FDA approval of ...
PMLive

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...
New Jersey Business Magazine

Novartis Receives FDA Approval for Spinal Muscular Atrophy Gene Replacement Therapy

The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

Samantha Ruth Prabhu’s Myositis journey: About the autoimmune condition and how the actor turned pain into real strength

South Indian star Samantha Ruth Prabhu revealed her myositis diagnosis in October 2022, a rare autoimmune disease causing ...
Everyday Health on MSN

Your Butt May Reveal Your Diabetes Risk

A new study finds that men with diabetes have areas of muscle thinning in their gluteus maximus while women show pockets of ...
Medical Dialogues

USFDA greenlights Novartis gene replacement therapy for spinal muscular atrophy

Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...

Rising medical costs? Here’s how people with disabilities can build a strong financial safety net

Financial planning for people with disabilities demands special attention. They face unique financial pressures, from recurring medical expenses to long-term care needs, making structured financial ...